IRBM announced a new agreement in the peptide therapeutics area with Merck & Co. Inc., continuing their long-standing history of collaboration that began in 2010.   “Our R&D peptide group have extensive expertise to help deliver high quality peptide drugs for a wide variety of therapeutic indications,” said Carlo Toniatti, chief science officer at IRBM. “We are thrilled to be collaborating on this project as part of our mission to advance impactful agents into the clinic.”   There ha...